Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma

This study has been completed.
Sponsor:
Collaborators:
Corixa Corporation
GlaxoSmithKline
Information provided by (Responsible Party):
Susan Knox, Stanford University
ClinicalTrials.gov Identifier:
NCT00490009
First received: June 20, 2007
Last updated: June 19, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)